Your Dentist May Be Able to Identify a New Sign of Alzheimer's
Alzheimer's disease is a complicated condition, with many different factors that influence when and if a person develops it. But the latest findings suggest what's happening in your mouth could be linked on some level with your brain health. Here's the deal.
Meet the expert: Jennifer Bramen, PhD, is a senior research scientist and director of neuroimaging at the Pacific Neuroscience Institute at Providence Saint John's Health Center in Santa Monica, CA; Mark S. Wolff, DDS, PhD, is dean of the University of Pennsylvania School of Dental Medicine
The study, published in PNAS Nexus, looked at 110 people over the age of 50 who participated in an online study that tracks brain health of middle-aged people in the UK. The participants were broken into two groups: One group had no detectable decline in brain function, while the others had mild cognitive impairment, a condition where people have more memory or thinking problems than others their age. People with mild cognitive impairment are at a higher risk of developing Alzheimer's disease or dementia, according to the National Institute on Aging (NIA).
The study participants provided the scientists with mouth rinse samples, which were then analyzed, allowing the researchers to break down the bacteria contained in each sample. The researchers discovered that certain bacteria found in the participants' mouths were linked with having better memory and attention; Others were associated with a higher risk of Alzheimer's disease.
Which bacteria are associated with memory and attention?
This study found that people who had large amounts of the bacteria Neisseria and Haemophilus had better memory and attention. They also could do complex tasks more easily, based on the findings.
Which bacteria are linked with memory loss?
The researchers found that people who had higher levels of the bacteria Porphyromonas (a key pathogen in chronic periodontitis) in their mouths were more likely to have memory problems. The bacteria Prevotella (also commonly found in peridontel disease) was also associated with people having the gene APOE4, which is linked to Alzheimer's disease.
There have been several studies that have linked bacteria in the mouth to dementia. Research has generally suggested that having higher levels of harmful bacteria in the mouth may raise the risk of bodily inflammation, which could potentially also raise the risk of developing Alzheimer's disease.
The researchers in this study theorized that harmful bacteria could get into the bloodstream and damage the brain, raising the risk of Alzheimer's disease. They also suggest that a bacterial imbalance could impact how much nitric oxide is formed from nitrate, a compound in vegetables. Nitric oxide is important for memory and communication in the brain.
But it's hard to say for sure that the bacteria causes dementia or issues with brain health, says Mark S. Wolff, DDS, PhD, dean of the University of Pennsylvania School of Dental Medicine.
'We need to be careful not to assert a cause and effect when both of these things may just be happening at the same time,' he says. 'People can have bad gum disease, and lots of bacteria, and develop Alzheimer's disease. Did one cause the other or did they just both occur because we weren't taking good care of our mouth while we were developing the Alzheimer's disease?'
Eating a plant-based diet seems to be a good start, according to Jennifer Bramen, PhD, a senior research scientist and director of neuroimaging at the Pacific Neuroscience Institute at Providence Saint John's Health Center in Santa Monica, CA.
Adding nitrate-rich foods like veggies into your diet 'can benefit the oral microbiome by promoting bacteria associated with better oral and cognitive health outcomes,' she says. This may also help to suppress bacteria that's linked with dementia, Bramen explains.
Again, it's hard to say at this point that these bacteria cause Alzheimer's disease, they're just linked. But it's never a bad idea to up your veggie intake.
You Might Also Like
Can Apple Cider Vinegar Lead to Weight Loss?
Bobbi Brown Shares Her Top Face-Transforming Makeup Tips for Women Over 50
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Cognito achieves enrolment target in trial of Spectris system for Alzheimer's
Cognito Therapeutics has reached its enrolment goal for the randomised, sham-controlled HOPE Study investigating the Spectris AD system's efficacy and safety in treating Alzheimer's disease. The double-blind trial, with 670 subjects enrolled, is set to use the company's neuromodulating device at home for 12 months. Carried out across 70 US clinical sites, the trial will be followed by a 12-month open-label extension trial. According to the company, the Spectris AD system will deliver synchronised light and sound stimulation at the 40Hz gamma frequency, which has previously shown promise in the OVERTURE feasibility study by preserving corpus callosum structure in subjects with Alzheimer's. Results from the study indicated a 76% and 77% decrease in cognitive and functional decline, respectively, and significant white matter preservation with a 69% decrease in whole brain atrophy over six months. Subjects in the HOPE Study's treatment group will receive Active Sensory Stimulation System treatment once a day while the control group will use a Sham Sensory Stimulation System. Study visits for consent, screening, and baseline assessments are scheduled, followed by three, six, nine (by phone), 12, and 13 months safety follow-ups. The primary aim of the study is to evaluate Spectris' efficacy in slowing Alzheimer's progression against sham for mild to moderate patients, measured functionally by the Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) assessment and the Mini-Mental State Exam (MMSE). A subset of clinical sites will participate in a substudy to assess additional fluid biomarkers. Subjects at these sites will undergo lumbar punctures to collect cerebrospinal fluid at baseline, three months, and 12 months. Cognito Therapeutics CEO Christian Howell said: 'Completing enrolment in this landmark trial marks a major step forward in our mission to deliver a better treatment option for people living with neurodegenerative conditions such as Alzheimer's.' The system remains investigational and is not yet available for sale. In 2023, Cognito secured $73m in Series B funding to further develop its wearable neuromodulation device for Alzheimer's. "Cognito achieves enrolment target in trial of Spectris system for Alzheimer's" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Miami Herald
21 hours ago
- Miami Herald
Mayo Clinic's AI tool identifies 9 dementia types, including Alzheimer's, with one scan
ROCHESTER, Minn. - Mayo Clinic researchers have developed a new artificial intelligence (AI) tool that helps clinicians identify brain activity patterns linked to nine types of dementia, including Alzheimer's disease, using a single, widely available scan - a transformative advance in early, accurate diagnosis. The tool, StateViewer, helped researchers identify the dementia type in 88% of cases, according to research published online on June 27, 2025, in Neurology, the medical journal of the American Academy of Neurology. It also enabled clinicians to interpret brain scans nearly twice as fast and with up to three times greater accuracy than standard workflows. Researchers trained and tested the AI on more than 3,600 scans, including images from patients with dementia and people without cognitive impairment. This innovation addresses a core challenge in dementia care: identifying the disease early and precisely, even when multiple conditions are present. As new treatments emerge, timely diagnosis helps match patients with the most appropriate care when it can have the greatest impact. The tool could bring advanced diagnostic support to clinics that lack neurology expertise. The rising toll of dementia Dementia affects more than 55 million people worldwide, with nearly 10 million new cases each year. Alzheimer's disease, the most common form, is now the fifth-leading cause of death globally. Diagnosing dementia typically requires cognitive tests, blood draws, imaging, clinical interviews and specialist referrals. Even with extensive testing, distinguishing conditions such as Alzheimer's, Lewy body dementia and frontotemporal dementia remains challenging, including for highly experienced specialists. StateViewer was developed under the direction of David Jones, M.D., a Mayo Clinic neurologist and director of the Mayo Clinic Neurology Artificial Intelligence Program. 'Every patient who walks into my clinic carries a unique story shaped by the brain's complexity,' Dr. Jones says. 'That complexity drew me to neurology and continues to drive my commitment to clearer answers. StateViewer reflects that commitment - a step toward earlier understanding, more precise treatment and, one day, changing the course of these diseases.' To bring that vision to life, Dr. Jones worked alongside Leland Barnard, Ph.D., a data scientist who leads the AI engineering behind StateViewer. 'As we were designing StateViewer, we never lost sight of the fact that behind every data point and brain scan was a person facing a difficult diagnosis and urgent questions,' Dr. Barnard says. 'Seeing how this tool could assist physicians with real-time, precise insights and guidance highlights the potential of machine learning for clinical medicine.' Turning brain patterns into clinical insight The tool analyzes a fluorodeoxyglucose positron emission tomography (FDG-PET) scan, which shows how the brain uses glucose for energy. It then compares the scan to a large database of scans from people with confirmed dementia diagnoses and identifies patterns that match specific types, or combinations, of dementia. Alzheimer's typically affects memory and processing regions, Lewy body dementia involves areas tied to attention and movement, and frontotemporal dementia alters regions responsible for language and behavior. StateViewer displays these patterns through color-coded brain maps that highlight key areas of brain activity, giving all clinicians, even those without neurology training, a visual explanation of what the AI sees and how it supports the diagnosis. Mayo Clinic researchers plan to expand the tool's use and will continue evaluating its performance in a variety of clinical settings. Copyright (C) 2025, Tribune Content Agency, LLC. Portions copyrighted by the respective providers.
Yahoo
a day ago
- Yahoo
Is Quest Diagnostics Stock a Smart Pick for Your Portfolio Now?
Quest Diagnostics Inc. DGX is investing in advanced diagnostics to deliver and scale innovative services that improve patient care and drive growth. The company's growth strategy includes pursuing value-creating, strategically aligned acquisitions using a disciplined investment approach. A strong focus on cost management adds to the the company continues to navigate a shifting U.S. healthcare system marked by several inherent risks. A rising debt burden is also concerning. In the past year, this Zacks Rank #2 (Buy) stock has rallied 27.3% compared with the industry's 6.6% growth and the S&P 500 composite's 11.7% rise. The renowned provider of diagnostic information services has a market capitalization of $20.05 billion. Quest Diagnostics has an earnings yield of 5.4% compared with the industry's yield of 4.3%. The company's earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 2%. Strong Potential of Advanced Diagnostics: In Advanced Diagnostics, DGX is focused on five major clinical areas — advanced cardiometabolic, autoimmune, brain health, oncology, and women's and reproductive health — to enable growth across its customer channels. In the first quarter of 2025, each of these areas delivered solid double-digit growth, significantly contributing to the total revenues. Brain Health gained from robust demand for AD-detect blood tests for assessing Alzheimer's disease risk, with plans underway to expand the portfolio with new biomarkers for Alzheimer's and other forms of dementia. Image Source: Zacks Investment Research In women's and reproductive health, Quest Diagnostics introduced a new self-collection option for a specimen for HPV cervical cancer screening at a doctor's office. The company also started receiving commercial orders for the Haystack MRD test for assessing the early risk of cancer recurrence. It anticipates generating revenues from the test this year. Progress With Acquisition Strategy: Quest Diagnostics puts a high emphasis on accretive outreach purchases, as well as other independent labs, to support its growth objectives. In 2024, the company completed eight acquisitions, all of which align with its criteria for growth, profitability and returns. The addition of LifeLabs strengthened its foothold in the Canadian market and created new growth opportunities. The company acquired Allina Health, a leading nonprofit health system serving Minnesota and western Wisconsin, and the laboratory business of three physician groups in New York. To increase the adoption of AI and digital pathology, Quest Diagnostics acquired PathAI Diagnostics. In addition, it completed the acquisition of lab assets from Ohio Health and University Hospitals, two leading nonprofit health systems in Ohio. For 2025, Quest Diagnostics plans to slow its acquisition pace and prioritize maximizing productivity from last year's completed deals. Strategic Imperative to Drive Operational Excellence: The company continues to target 3% annual cost savings and productivity improvements through its Invigorate cost-savings program, which includes structured plans to drive savings and improve productivity across the value chain. Quest Diagnostics is also automating several areas of its laboratories, from tuberculosis testing to cervical cancer screening. The company also recently announced Project Nova, a new IT initiative to modernize its systems architecture, reduce IT costs over the long term and support its ability to optimize data insights and GenAI. In March 2025, DGX announced a collaboration with Google Cloud to streamline data management and employ GenAI to personalize customer and employee experiences. Escalating Debt Level: As of the end of the first quarter of 2025, the long-term debt totaled $5.86 billion, while cash and cash equivalents were just $188 million. The current portion of the debt was $1 million. Moreover, a higher debt level induces higher interest payments, which come along with the risk of failure to pay the same. The times interest ratio, which indicates the company's capacity to pay interest, slipped 0.6% sequentially to 6.3%. Unstable Macroeconomic Backdrop: Government payers, such as Medicare and Medicaid, have taken steps to reduce the utilization and reimbursement of healthcare services, including clinical testing services. Further, the industry-wide trend of consolidation has led to larger insurance plans with significant bargaining power, making it difficult for Quest Diagnostics to negotiate fee arrangements and possibly limiting access to its newer innovative solutions. Also, with the new U.S. administration in place, any regulatory changes could have a material adverse effect on the company's business. The Zacks Consensus Estimate for Quest Diagnostics' 2025 earnings per share (EPS) has increased 1 cent to $9.70 in the past 30 days. The consensus estimate for the company's 2025 revenues is pegged at $10.78 billion. This suggests 9.2% growth from the year-ago reported number. Some other top-ranked stocks in the broader medical space are Phibro Animal Health PAHC, Cardinal Health CAH and Cencora COR. Phibro Animal Health has an estimated long-term earnings growth rate of 26% compared with the industry's 15.7%. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 30.6%. Its shares have rallied 49.8% compared with the industry's 14.3% growth in the past year. PAHC sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today's Zacks #1 Rank stocks here. Cardinal Health, currently carrying a Zacks Rank #2, has an estimated long-term earnings growth rate of 10.9% compared with the industry's 9.9% growth. Shares of the company have surged 74.1% compared with the industry's modest 0.9% gain. CAH's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 10.3%. Cencora, carrying a Zacks Rank #2 at present, has an earnings yield of 5.3% compared with the industry's 3.7%. Shares of the company have rallied 34.1% against the industry's 14.5% decline. COR's earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 6%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Quest Diagnostics Incorporated (DGX) : Free Stock Analysis Report Cardinal Health, Inc. (CAH) : Free Stock Analysis Report Cencora, Inc. (COR) : Free Stock Analysis Report Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data